相关实验视频

Updated: Sep 17, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

在阿纳普拉斯性淋巴瘤激酶阳性肺癌中抵抗机制

Parnia Behinaein¹, Shirish M Gadgeel², Ramandeep Rattan³

¹Department of Surgery, Henry Ford Health, Detroit, MI, United States.

Critical reviews in oncology/hematology

|June 28, 2025

概括

无细胞淋巴瘤激酶 (ALK) 阳性非小细胞肺癌 (NSCLC) 呈现出独特的患者特征和疾病过程. 耐药性持久细胞可能导致ALK-NSCLC的复发,需要新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

非小细胞肺癌 (NSCLC) 包括各种分子亚型,影响临床行为.
无性淋巴瘤激酶 (ALK) 阳性NSCLC (ALK-NSCLC) 呈现出不同的患者人口统计和预后,通常包括年轻患者,吸烟史较少,存活时间较长.
在ALK-NSCLC中疾病复发是一个重大的临床挑战.

研究的目的:

审查ALK-NSCLC中耐药性持久细胞 (DTP) 的现象.
探索DTP形成和持久性的潜在机制解释.
讨论新兴的治疗策略,旨在消除DTP,以预防或克服复发.

主要方法:

对ALK-NSCLC,DTP和治疗干预措施研究的文献综述.
分析与ALK-NSCLC中DTP生物学相关的临床和临床前数据.
综合当前的理解和未来的方向在准DTPs.

主要成果:

患有ALK-NSCLC的患者往往表现出独特的临床特征和延长的疾病过程.
耐药性持续性 (DTP) 细胞被认为是驱动初始治疗后疾病复发的关键机制.
了解DTPs的生物学对于开发有效疗法至关重要.

结论:

耐药性持久细胞是ALK-NSCLC持续缓解的关键障碍.
针对DTP提供了一个有希望的途径,以改善ALK-NSCLC患者的长期结果.
对DTP机制和新型治疗策略的进一步研究是有必要的.

关键词:

有ALK阳性的肺癌.自自是一种自的过程.卡路里限制卡路里限制组合疗法是一种联合疗法.药物耐药性药物耐药性药物耐药性免疫调节免疫调节代谢适应代谢适应线粒体代谢的代谢过程铁氨酸激酶抑制剂铁氨酸激酶抑制剂

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...